Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321958 | 0.86 | — | — | |
| SCHEMBL3069909 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL17841947 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL7164543 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL13099488 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL19936530 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL11273936 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL10976205 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL6585676 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TRPA1MGAMGAASI | |
| SCHEMBL27830172 | 0.81 | ALDH1A1 (0.45) | ALDH1A1TRPA1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060093554-A1 | Galenical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| EP-0784052-B1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | AVENTIS HOLDINGS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| CN-1469757-A | Use of metal complexes containing perfluoroalkyl as contrast agents in MR-imaging for the representation of plaques, tumours and necroses | ���ֹɷݹ�˾ | 2004-01-21 | — | — | CN | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| EP-0784052-A1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-4920131-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4918081-A | Quinoline derivatives and use thereof as antagonists of leukotriene d4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0348155-A1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | ALDH1A1 4799/4885TRPA1 730/4885MGAM 1191/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | ALDH1A1 4595/4885TRPA1 526/4885MGAM 1681/4885 |
| US-20060093554-A1 | Galenical formulations | GALC, GALR2, GALR1 | ALDH1A1 3897/4885TRPA1 1195/4885MGAM 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.